{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:23:20Z","timestamp":1792034600628,"version":"4.4.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K15997"],"award-info":[{"award-number":["21K15997"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical landscape of chronic liver disease has changed with effective antiviral therapies, enabling the eradication of hepatitis C virus and the durable suppression of hepatitis B virus replication. Despite these advances, patients remain at risk for hepatocellular carcinoma (HCC) and other liver-related complications, but the growing burden of metabolic dysfunction-associated steatotic liver disease (MASLD) has created new challenges for clinical practice. These trends emphasize the need for reliable, noninvasive biomarkers that can stratify risk and guide long-term management across diverse etiologies. Growth differentiation factor 15 (GDF15), a stress-inducible cytokine, has attracted increasing interest as a promising biomarker. Its expression is induced by metabolic, oxidative, and inflammatory stress, and circulating levels increase with disease progression. Elevated serum GDF15 is consistently associated with fibrosis severity, HCC risk, hepatic decompensation, and mortality. Importantly, GDF15 is not merely a surrogate of fibrosis; rather, it integrates hepatocellular and stromal stress pathways and captures residual risk beyond fibrosis stage, liver function scores, and conventional biomarkers. In addition to its prognostic association, GDF15 has diverse biological effects. It may act as a protective response by limiting inflammation and cellular injury; yet, in other contexts, it contributes to fibrogenesis, tumor progression, immunosuppression, and cachexia. These dual roles highlight both the potential and the complexity of targeting GDF15 in therapeutic strategies. Collectively, the results of the current study indicate that GDF15 represents a promising biomarker in chronic hepatic diseases and is clinically independent of hepatic fibrosis. Further work is needed to clarify the underlying mechanisms, validate the prognostic utility, and determine whether GDF15 can be developed as a therapeutic target within precision medicine approaches.<\/jats:p>","DOI":"10.1007\/s00535-025-02336-7","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:14:20Z","timestamp":1766495660000},"page":"117-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-9703","authenticated-orcid":false,"given":"Yuta","family":"Myojin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2488-7315","authenticated-orcid":false,"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2336_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00535-022-01893-5","volume":"57","author":"K Okushin","year":"2022","unstructured":"Okushin K, Tateishi R, Takahashi A, et al. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J Gastroenterol. 2022;57:587\u201397. https:\/\/doi.org\/10.1007\/s00535-022-01893-5.","journal-title":"J Gastroenterol"},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/hepr.14047","volume":"54","author":"H Enomoto","year":"2024","unstructured":"Enomoto H, Akuta N, Hikita H, et al. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: updated nationwide survey from 2018 to 2021. Hepatol Res. 2024;54:763\u201372. https:\/\/doi.org\/10.1111\/hepr.14047.","journal-title":"Hepatol Res"},{"key":"2336_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453\u201364. https:\/\/doi.org\/10.1016\/s0140-6736(18)32111-1.","journal-title":"Lancet"},{"key":"2336_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1053\/j.gastro.2020.11.057","volume":"160","author":"JM Paik","year":"2021","unstructured":"Paik JM, Younossi Y, Henry L, et al. Recent trends in the global burden of hepatitis B virus: 2007\u20132017. Gastroenterology. 2021;160:1845-6.e3. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.057.","journal-title":"Gastroenterology"},{"key":"2336_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264-78.e4. https:\/\/doi.org\/10.1053\/j.gastro.2019.07.033.","journal-title":"Gastroenterology"},{"key":"2336_CR6","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/hepr.14225","volume":"55","author":"K Murai","year":"2025","unstructured":"Murai K, Hikita H, Yamada R, et al. The risk of developing hepatocellular carcinoma persists in chronic hepatitis B patients even after the long-term administration of nucleos(t)ide analogs. Hepatol Res. 2025;55:1228\u201338. https:\/\/doi.org\/10.1111\/hepr.14225.","journal-title":"Hepatol Res"},{"key":"2336_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/hepr.13806","volume":"52","author":"Y Tahata","year":"2022","unstructured":"Tahata Y, Sakamori R, Yamada R, et al. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. Hepatol Res. 2022;52:824\u201332. https:\/\/doi.org\/10.1111\/hepr.13806.","journal-title":"Hepatol Res"},{"key":"2336_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jhep.2016.10.028","volume":"66","author":"NZ Janjua","year":"2017","unstructured":"Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66:504\u201313. https:\/\/doi.org\/10.1016\/j.jhep.2016.10.028.","journal-title":"J Hepatol"},{"key":"2336_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56:951\u201363. https:\/\/doi.org\/10.1007\/s00535-021-01796-x.","journal-title":"J Gastroenterol"},{"key":"2336_CR10","doi-asserted-by":"publisher","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54707.","journal-title":"JAMA Netw Open"},{"key":"2336_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/apt.18451","volume":"61","author":"S Owrangi","year":"2025","unstructured":"Owrangi S, Paik JM, Golabi P, et al. Meta-analysis: global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2025;61:433\u201343. https:\/\/doi.org\/10.1111\/apt.18451.","journal-title":"Aliment Pharmacol Ther"},{"key":"2336_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/apt.17158","volume":"56","author":"L Henry","year":"2022","unstructured":"Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56:942\u201356. https:\/\/doi.org\/10.1111\/apt.17158.","journal-title":"Aliment Pharmacol Ther"},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043.","journal-title":"Gastroenterology"},{"key":"2336_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.70034","author":"K Sakai","year":"2025","unstructured":"Sakai K, Shima T, Oya H, et al. Association between liver fibrosis and cause-specific mortality in Japanese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a prospective cohort study\/liver fibrosis and mortality in Japanese MASLD. Hepatol Res. 2025. https:\/\/doi.org\/10.1111\/hepr.70034.","journal-title":"Hepatol Res"},{"key":"2336_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.035","author":"JT Grady","year":"2025","unstructured":"Grady JT, Cyrus JW, Sterling RK. Novel noninvasive tests for liver fibrosis: moving beyond simple tests in metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.035.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2336_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/HEP.0000000000000852","volume":"81","author":"A Duarte-Rojo","year":"2025","unstructured":"Duarte-Rojo A, Taouli B, Leung DH, et al. Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD practice guideline. Hepatology. 2025;81:725\u201348. https:\/\/doi.org\/10.1097\/HEP.0000000000000852.","journal-title":"Hepatology"},{"key":"2336_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/apt.18063","volume":"60","author":"S Kumazaki","year":"2024","unstructured":"Kumazaki S, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Aliment Pharmacol Ther. 2024;60:327\u201339. https:\/\/doi.org\/10.1111\/apt.18063.","journal-title":"Aliment Pharmacol Ther"},{"key":"2336_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/apt.16691","volume":"55","author":"Y Myojin","year":"2022","unstructured":"Myojin Y, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther. 2022;55:422\u201333. https:\/\/doi.org\/10.1111\/apt.16691.","journal-title":"Aliment Pharmacol Ther"},{"key":"2336_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14111","author":"E Sometani","year":"2024","unstructured":"Sometani E, Hikita H, Murai K, et al. High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatol Res. 2024. https:\/\/doi.org\/10.1111\/hepr.14111.","journal-title":"Hepatol Res"},{"key":"2336_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.70041","author":"Y Myojin","year":"2025","unstructured":"Myojin Y, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 can be a novel biomarker to predict the prognosis of patients with hepatitis C virus cirrhosis after virus elimination. Hepatol Res. 2025. https:\/\/doi.org\/10.1111\/hepr.70041.","journal-title":"Hepatol Res"},{"key":"2336_CR21","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","volume":"94","author":"MR Bootcov","year":"1997","unstructured":"Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 1997;94:11514\u20139. https:\/\/doi.org\/10.1073\/pnas.94.21.11514.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2336_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0378-1119(97)00485-x","volume":"203","author":"LN Lawton","year":"1997","unstructured":"Lawton LN, Bonaldo MF, Jelenc PC, et al. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997;203:17\u201326. https:\/\/doi.org\/10.1016\/s0378-1119(97)00485-x.","journal-title":"Gene"},{"key":"2336_CR23","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.isci.2021.102181","volume":"24","author":"SG Kang","year":"2021","unstructured":"Kang SG, Choi MJ, Jung SB, et al. Differential roles of GDF15 and FGF21 in systemic metabolic adaptation to the mitochondrial integrated stress response. iScience. 2021;24:102181. https:\/\/doi.org\/10.1016\/j.isci.2021.102181.","journal-title":"iScience"},{"key":"2336_CR24","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1038\/emboj.2010.81","volume":"29","author":"J Ye","year":"2010","unstructured":"Ye J, Kumanova M, Hart LS, et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 2010;29:2082\u201396. https:\/\/doi.org\/10.1038\/emboj.2010.81.","journal-title":"EMBO J"},{"key":"2336_CR25","doi-asserted-by":"publisher","first-page":"20331","DOI":"10.1074\/jbc.M411275200","volume":"280","author":"CN Roybal","year":"2005","unstructured":"Roybal CN, Hunsaker LA, Barbash O, et al. The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism. J Biol Chem. 2005;280:20331\u20139. https:\/\/doi.org\/10.1074\/jbc.M411275200.","journal-title":"J Biol Chem"},{"key":"2336_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-020-2076-4","volume":"579","author":"E Fessler","year":"2020","unstructured":"Fessler E, Eckl EM, Schmitt S, et al. A pathway coordinated by DELE1 relays mitochondrial stress to the cytosol. Nature. 2020;579:433\u20137. https:\/\/doi.org\/10.1038\/s41586-020-2076-4.","journal-title":"Nature"},{"key":"2336_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12985-020-01362-6","volume":"17","author":"Y Liu","year":"2020","unstructured":"Liu Y, Wang M, Cheng A, et al. The role of host eIF2\u03b1 in viral infection. Virol J. 2020;17:112. https:\/\/doi.org\/10.1186\/s12985-020-01362-6.","journal-title":"Virol J"},{"key":"2336_CR28","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, et al. The integrated stress response. EMBO Rep. 2016;17:1374\u201395. https:\/\/doi.org\/10.15252\/embr.201642195.","journal-title":"EMBO Rep"},{"key":"2336_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","volume":"29","author":"S Patel","year":"2019","unstructured":"Patel S, Alvarez-Guaita A, Melvin A, et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 2019;29:707-18.e8. https:\/\/doi.org\/10.1016\/j.cmet.2018.12.016.","journal-title":"Cell Metab"},{"key":"2336_CR30","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1053\/j.gastro.2020.12.015","volume":"160","author":"Y Myojin","year":"2021","unstructured":"Myojin Y, Hikita H, Sugiyama M, et al. Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production. Gastroenterology. 2021;160:1741-54.e16. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.015.","journal-title":"Gastroenterology"},{"key":"2336_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","volume":"28","author":"VWW Tsai","year":"2018","unstructured":"Tsai VWW, Husaini Y, Sainsbury A, et al. The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28:353\u201368. https:\/\/doi.org\/10.1016\/j.cmet.2018.07.018.","journal-title":"Cell Metab"},{"key":"2336_CR32","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican SE, Lin-Schmidt X, Chin CN, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23:1150\u20137. https:\/\/doi.org\/10.1038\/nm.4392.","journal-title":"Nat Med"},{"key":"2336_CR33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang L, Chang CC, Sun Z, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med. 2017;23:1158\u201366. https:\/\/doi.org\/10.1038\/nm.4394.","journal-title":"Nat Med"},{"key":"2336_CR34","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.tem.2020.10.004","volume":"31","author":"L Rochette","year":"2020","unstructured":"Rochette L, Zeller M, Cottin Y, et al. Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets. Trends Endocrinol Metab. 2020;31:939. https:\/\/doi.org\/10.1016\/j.tem.2020.10.004.","journal-title":"Trends Endocrinol Metab"},{"key":"2336_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-physiol-022020-045449","volume":"83","author":"SN Breit","year":"2021","unstructured":"Breit SN, Brown DA, Tsai VW. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe? Annu Rev Physiol. 2021;83:127\u201351. https:\/\/doi.org\/10.1146\/annurev-physiol-022020-045449.","journal-title":"Annu Rev Physiol"},{"key":"2336_CR36","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41586-023-06921-9","volume":"625","author":"M Fejzo","year":"2024","unstructured":"Fejzo M, Rocha N, Cimino I, et al. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature. 2024;625:760\u20137. https:\/\/doi.org\/10.1038\/s41586-023-06921-9.","journal-title":"Nature"},{"key":"2336_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"JY Hsu","year":"2017","unstructured":"Hsu JY, Crawley S, Chen M, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature. 2017;550:255\u20139. https:\/\/doi.org\/10.1038\/nature24042.","journal-title":"Nature"},{"key":"2336_CR38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","volume":"178","author":"HH Luan","year":"2019","unstructured":"Luan HH, Wang A, Hilliard BK, et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178:1231. https:\/\/doi.org\/10.1016\/j.cell.2019.07.033.","journal-title":"Cell"},{"key":"2336_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011036","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Cai H, Nie W, et al. Ectopic expression of GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL\u2013RET cascade. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-011036.","journal-title":"J Immunother Cancer"},{"key":"2336_CR40","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1515\/cclm-2022-0135","volume":"60","author":"P Welsh","year":"2022","unstructured":"Welsh P, Kimenai DM, Marioni RE, et al. Reference ranges for GDF-15, and risk factors associated with GDF-15, in a large general population cohort. Clin Chem Lab Med. 2022;60:1820. https:\/\/doi.org\/10.1515\/cclm-2022-0135.","journal-title":"Clin Chem Lab Med"},{"key":"2336_CR41","doi-asserted-by":"publisher","first-page":"100651","DOI":"10.1016\/j.ijcha.2020.100651","volume":"31","author":"H Yazawa","year":"2020","unstructured":"Yazawa H, Fukuda T, Kaneda H, et al. Association of serum growth differentiation factor-15 with eGFR and hemoglobin in healthy older females. IJC Heart Vasc. 2020;31:100651. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100651.","journal-title":"IJC Heart Vasc"},{"key":"2336_CR42","doi-asserted-by":"publisher","first-page":"e0248980","DOI":"10.1371\/journal.pone.0248980","volume":"16","author":"U Andersson-Hall","year":"2021","unstructured":"Andersson-Hall U, Svedin P, Mallard C, et al. Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy. PLoS ONE. 2021;16:e0248980. https:\/\/doi.org\/10.1371\/journal.pone.0248980.","journal-title":"PLoS ONE"},{"key":"2336_CR43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/uog.22070","volume":"56","author":"D Wertaschnigg","year":"2020","unstructured":"Wertaschnigg D, Rolnik DL, Nie G, et al. Second- and third-trimester serum levels of growth-differentiation factor-15 in prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2020;56:879. https:\/\/doi.org\/10.1002\/uog.22070.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2336_CR44","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cyto.2016.05.002","volume":"83","author":"Q Chen","year":"2016","unstructured":"Chen Q, Wang Y, Zhao M, et al. Serum levels of GDF15 are reduced in preeclampsia and the reduction is more profound in late-onset than early-onset cases. Cytokine. 2016;83:226\u201330. https:\/\/doi.org\/10.1016\/j.cyto.2016.05.002.","journal-title":"Cytokine"},{"key":"2336_CR45","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/jdi.13488","volume":"12","author":"E Li","year":"2021","unstructured":"Li E, Chen P, Lu J, et al. Serum growth differentiation factor 15 is closely associated with metabolic abnormalities in Chinese pregnant women. J Diabetes Investig. 2021;12:1501. https:\/\/doi.org\/10.1111\/jdi.13488.","journal-title":"J Diabetes Investig"},{"key":"2336_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/plac.2002.0881","volume":"24","author":"AB Marjono","year":"2003","unstructured":"Marjono AB, Brown DA, Horton KE, et al. Macrophage inhibitory cytokine-1 in gestational tissues and maternal serum in normal and pre-eclamptic pregnancy. Placenta. 2003;24:100\u20136. https:\/\/doi.org\/10.1053\/plac.2002.0881.","journal-title":"Placenta"},{"key":"2336_CR47","doi-asserted-by":"publisher","first-page":"851534","DOI":"10.3389\/fped.2022.851534","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, Li S, Qiu Y, et al. Circulating FGF21 and GDF15 as biomarkers for screening, diagnosis, and severity assessment of primary mitochondrial disorders in children. Front Pediatr. 2022;10:851534. https:\/\/doi.org\/10.3389\/fped.2022.851534.","journal-title":"Front Pediatr"},{"key":"2336_CR48","doi-asserted-by":"publisher","first-page":"e0148709","DOI":"10.1371\/journal.pone.0148709","volume":"11","author":"R Montero","year":"2016","unstructured":"Montero R, Yubero D, Villarroya J, et al. GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PLoS ONE. 2016;11:e0148709. https:\/\/doi.org\/10.1371\/journal.pone.0148709.","journal-title":"PLoS ONE"},{"key":"2336_CR49","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1212\/WNL.0000000000002705","volume":"86","author":"RL Davis","year":"2016","unstructured":"Davis RL, Liang C, Sue CM. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology. 2016;86:2010\u20135. https:\/\/doi.org\/10.1212\/WNL.0000000000002705.","journal-title":"Neurology"},{"key":"2336_CR50","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1212\/WNL.0000000000003374","volume":"87","author":"JM Lehtonen","year":"2016","unstructured":"Lehtonen JM, Forsstr\u00f6m S, Bottani E, et al. FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders. Neurology. 2016;87:2290\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000003374.","journal-title":"Neurology"},{"key":"2336_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2021.12.001","volume":"135","author":"LG Riley","year":"2022","unstructured":"Riley LG, Nafisinia M, Menezes MJ, et al. FGF21 outperforms GDF15 as a diagnostic biomarker of mitochondrial disease in children. Mol Genet Metab. 2022;135:63\u201371. https:\/\/doi.org\/10.1016\/j.ymgme.2021.12.001.","journal-title":"Mol Genet Metab"},{"key":"2336_CR52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.mito.2021.08.011","volume":"60","author":"A Huddar","year":"2021","unstructured":"Huddar A, Govindaraj P, Chiplunkar S, et al. Serum fibroblast growth factor 21 and growth differentiation factor 15: two sensitive biomarkers in the diagnosis of mitochondrial disorders. Mitochondrion. 2021;60:170\u20137. https:\/\/doi.org\/10.1016\/j.mito.2021.08.011.","journal-title":"Mitochondrion"},{"key":"2336_CR53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0042-114220","volume":"125","author":"SA Yuca","year":"2017","unstructured":"Yuca SA, Cimbek EA, \u015een Y, et al. The relationship between metabolic parameters, cardiac parameters and MIC-1\/GDF15 in obese children. Exp Clin Endocrinol Diabetes. 2017;125:86\u201390. https:\/\/doi.org\/10.1055\/s-0042-114220.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2336_CR54","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3346\/jkms.2016.31.9.1413","volume":"31","author":"MY Shin","year":"2016","unstructured":"Shin MY, Kim JM, Kang YE, et al. Association between growth differentiation factor 15 (GDF15) and cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus. J Korean Med Sci. 2016;31:1413\u20138. https:\/\/doi.org\/10.3346\/jkms.2016.31.9.1413.","journal-title":"J Korean Med Sci"},{"key":"2336_CR55","doi-asserted-by":"publisher","first-page":"30138","DOI":"10.1038\/s41598-025-14846-8","volume":"15","author":"A Schmid","year":"2025","unstructured":"Schmid A, Wilfurth E, H\u00f6pfinger A, et al. Characterization of growth differentiation factor 15 (GDF15) as a neurotropic adipokine permeable to the brain. Sci Rep. 2025;15:30138. https:\/\/doi.org\/10.1038\/s41598-025-14846-8.","journal-title":"Sci Rep"},{"key":"2336_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113033","author":"SW Weng","year":"2022","unstructured":"Weng SW, Chen WC, Shen FC, et al. Circulating growth differentiation factor 15 is associated with diabetic neuropathy. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11113033.","journal-title":"J Clin Med"},{"key":"2336_CR57","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.2147\/DMSO.S454531","volume":"17","author":"Y Li","year":"2024","unstructured":"Li Y, Wang Y, Cao Y, et al. Correlation between growth differentiation factor-15 and peripheral neuropathy in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2024;17:3019\u201328. https:\/\/doi.org\/10.2147\/DMSO.S454531.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2336_CR58","doi-asserted-by":"publisher","first-page":"e33044","DOI":"10.1016\/j.heliyon.2024.e33044","volume":"10","author":"Q Liu","year":"2024","unstructured":"Liu Q, Qin L, Liang Y, et al. Correlations between growth differentiation factor 15 (GDF-15) serum levels and gene polymorphism with type 2 diabetes mellitus. Heliyon. 2024;10:e33044. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33044.","journal-title":"Heliyon"},{"key":"2336_CR59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12933-020-01020-9","volume":"19","author":"X He","year":"2020","unstructured":"He X, Su J, Ma X, et al. The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes. Cardiovasc Diabetol. 2020;19:40. https:\/\/doi.org\/10.1186\/s12933-020-01020-9.","journal-title":"Cardiovasc Diabetol"},{"key":"2336_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13098-025-01588-w","volume":"17","author":"WC Chuang","year":"2025","unstructured":"Chuang WC, Chu CH, Yao CS, et al. The value of growth differentiation factor 15 as a biomarker for peripheral artery disease in diabetes patients. Diabetol Metab Syndr. 2025;17:31. https:\/\/doi.org\/10.1186\/s13098-025-01588-w.","journal-title":"Diabetol Metab Syndr"},{"key":"2336_CR61","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3389\/fendo.2018.00793","volume":"9","author":"J Zhao","year":"2018","unstructured":"Zhao J, Li M, Chen Y, et al. Elevated serum growth differentiation factor 15 levels in hyperthyroid patients. Front Endocrinol (Lausanne). 2018;9:793. https:\/\/doi.org\/10.3389\/fendo.2018.00793.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2336_CR62","doi-asserted-by":"publisher","first-page":"460","DOI":"10.5937\/jomb0-24662","volume":"39","author":"M Vasanthi","year":"2020","unstructured":"Vasanthi M, Adole PS, Pandit VR, et al. Assessment of serum tenascin-C and growth differentiation factor-15 among type 2 diabetes mellitus patients with and without acute coronary syndrome. J Med Biochem. 2020;39:460\u20136. https:\/\/doi.org\/10.5937\/jomb0-24662.","journal-title":"J Med Biochem"},{"key":"2336_CR63","doi-asserted-by":"publisher","first-page":"9820210","DOI":"10.1155\/2019\/9820210","volume":"2019","author":"S Liu","year":"2019","unstructured":"Liu S, Chen X, Wang H, et al. Association of GDF-15 and syntax score in patient with acute myocardial infarction. Cardiovasc Ther. 2019;2019:9820210. https:\/\/doi.org\/10.1155\/2019\/9820210.","journal-title":"Cardiovasc Ther"},{"key":"2336_CR64","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/ejhf.117","volume":"16","author":"G Fuernau","year":"2014","unstructured":"Fuernau G, Poenisch C, Eitel I, et al. Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial. Eur J Heart Fail. 2014;16:880\u20137. https:\/\/doi.org\/10.1002\/ejhf.117.","journal-title":"Eur J Heart Fail"},{"key":"2336_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5937\/jomb0-50741","volume":"44","author":"R Guihong","year":"2025","unstructured":"Guihong R, Xiao W, Xinling Q, et al. Plasma biomarkers for predicting heart failure in patients with acute myocardial infarction. J Med Biochem. 2025;44:69\u201376. https:\/\/doi.org\/10.5937\/jomb0-50741.","journal-title":"J Med Biochem"},{"key":"2336_CR66","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.amjcard.2011.05.028","volume":"108","author":"A Dominguez-Rodriguez","year":"2011","unstructured":"Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction. Am J Cardiol. 2011;108:955\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2011.05.028.","journal-title":"Am J Cardiol"},{"key":"2336_CR67","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/1755-5922.12184","volume":"34","author":"X Wang","year":"2016","unstructured":"Wang X, Chen LL, Zhang Q. Increased serum level of growth differentiation factor 15 (GDF-15) is associated with coronary artery disease. Cardiovasc Ther. 2016;34:138\u201343. https:\/\/doi.org\/10.1111\/1755-5922.12184.","journal-title":"Cardiovasc Ther"},{"key":"2336_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18502\/jthc.v16i1.6595","volume":"16","author":"F Raygan","year":"2021","unstructured":"Raygan F, Etminan A, Mohammadi H, et al. Serum levels of growth differentiation factor-15 as an inflammatory marker in patients with unstable angina pectoris. J Tehran Heart Cent. 2021;16:15\u20139. https:\/\/doi.org\/10.18502\/jthc.v16i1.6595.","journal-title":"J Tehran Heart Cent"},{"key":"2336_CR69","doi-asserted-by":"publisher","first-page":"8360936","DOI":"10.1155\/2020\/8360936","volume":"2020","author":"Y Wei","year":"2020","unstructured":"Wei Y, Liu S, Yu H, et al. The predictive value of growth differentiation factor-15 in recurrence of atrial fibrillation after catheter ablation. Mediat Inflamm. 2020;2020:8360936. https:\/\/doi.org\/10.1155\/2020\/8360936.","journal-title":"Mediat Inflamm"},{"key":"2336_CR70","doi-asserted-by":"publisher","first-page":"101114","DOI":"10.1016\/j.ijcha.2022.101114","volume":"42","author":"R Nishikawa","year":"2022","unstructured":"Nishikawa R, Fukuda T, Haruyama A, et al. Association between serum GDF-15, myostatin, and sarcopenia in cardiovascular surgery patients. IJC Heart Vasc. 2022;42:101114. https:\/\/doi.org\/10.1016\/j.ijcha.2022.101114.","journal-title":"IJC Heart Vasc"},{"key":"2336_CR71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fcvm.2020.00103","volume":"7","author":"S Sarkar","year":"2020","unstructured":"Sarkar S, Legere S, Haidl I, et al. Serum GDF15, a promising biomarker in obese patients undergoing heart surgery. Front Cardiovasc Med. 2020;7:103. https:\/\/doi.org\/10.3389\/fcvm.2020.00103.","journal-title":"Front Cardiovasc Med"},{"key":"2336_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091960","author":"T Kato","year":"2021","unstructured":"Kato T, Nakajima T, Fukuda T, et al. Preoperative serum GDF-15, endothelin-1 levels, and intraoperative factors as short-term operative risks for patients undergoing cardiovascular surgery. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10091960.","journal-title":"J Clin Med"},{"key":"2336_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101576","author":"T Nakajima","year":"2019","unstructured":"Nakajima T, Shibasaki I, Sawaguchi T, et al. Growth differentiation factor-15 (GDF-15) is a biomarker of muscle wasting and renal dysfunction in preoperative cardiovascular surgery patients. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8101576.","journal-title":"J Clin Med"},{"key":"2336_CR74","doi-asserted-by":"publisher","first-page":"e82508","DOI":"10.7759\/cureus.82508","volume":"17","author":"T Fukuda","year":"2025","unstructured":"Fukuda T, Kato T, Kanazawa Y, et al. Prediction of Japan score and society of thoracic surgeons risk scores for patients undergoing cardiovascular surgery by serum growth differentiation factor-15 and endothelin-1 levels. Cureus. 2025;17:e82508. https:\/\/doi.org\/10.7759\/cureus.82508.","journal-title":"Cureus"},{"key":"2336_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/life15030387","author":"A Garganeeva","year":"2025","unstructured":"Garganeeva A, Kuzheleva E, Tukish O, et al. Predictors of adverse cardiovascular events after CABG in patients with previous heart failure. Life (Basel). 2025. https:\/\/doi.org\/10.3390\/life15030387.","journal-title":"Life (Basel)"},{"key":"2336_CR76","doi-asserted-by":"publisher","first-page":"741","DOI":"10.33963\/v.phj.100996","volume":"82","author":"W Szczurek-Wasilewicz","year":"2024","unstructured":"Szczurek-Wasilewicz W, Warmusz O, Skrzypek M, et al. Growth differentiation factor-15 and routine laboratory parameters are associated with one-year mortality in patients with end-stage heart failure undergoing heart transplantation evaluation. Kardiol Pol. 2024;82:741\u20138. https:\/\/doi.org\/10.33963\/v.phj.100996.","journal-title":"Kardiol Pol"},{"key":"2336_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041130","author":"P Jirak","year":"2020","unstructured":"Jirak P, Pistulli R, Lichtenauer M, et al. Expression of the novel cardiac biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF patients compared to ICM, DCM, and controls. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9041130.","journal-title":"J Clin Med"},{"key":"2336_CR78","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cjca.2013.12.010","volume":"30","author":"Y Izumiya","year":"2014","unstructured":"Izumiya Y, Hanatani S, Kimura Y, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol. 2014;30:338\u201344. https:\/\/doi.org\/10.1016\/j.cjca.2013.12.010.","journal-title":"Can J Cardiol"},{"key":"2336_CR79","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jjcc.2019.12.008","volume":"75","author":"Y Kagiyama","year":"2020","unstructured":"Kagiyama Y, Yatsuga S, Kinoshita M, et al. Growth differentiation factor 15 as a useful biomarker of heart failure in young patients with unrepaired congenital heart disease of left to right shunt. J Cardiol. 2020;75:697\u2013701. https:\/\/doi.org\/10.1016\/j.jjcc.2019.12.008.","journal-title":"J Cardiol"},{"key":"2336_CR80","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.hlc.2019.03.004","volume":"29","author":"M Mirna","year":"2020","unstructured":"Mirna M, Rohm I, Jirak P, et al. Analysis of novel cardiovascular biomarkers in patients with pulmonary hypertension (PH). Heart Lung Circ. 2020;29:337\u201344. https:\/\/doi.org\/10.1016\/j.hlc.2019.03.004.","journal-title":"Heart Lung Circ"},{"key":"2336_CR81","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1159\/000501096","volume":"28","author":"E S\u00f6kmen","year":"2019","unstructured":"S\u00f6kmen E, U\u00e7ar C, Sivri S, et al. Association between growth differentiation factor 15 and non-dipping circadian pattern in patients with newly diagnosed essential hypertension. Med Princ Pract. 2019;28:566\u201372. https:\/\/doi.org\/10.1159\/000501096.","journal-title":"Med Princ Pract"},{"key":"2336_CR82","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000455907","volume":"7","author":"AS You","year":"2017","unstructured":"You AS, Kalantar-Zadeh K, Lerner L, et al. Association of growth differentiation factor 15 with mortality in a prospective hemodialysis cohort. Cardiorenal Med. 2017;7:158\u201368. https:\/\/doi.org\/10.1159\/000455907.","journal-title":"Cardiorenal Med"},{"key":"2336_CR83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43066-021-00075-x","volume":"11","author":"HMA Abou Zaghla","year":"2021","unstructured":"Abou Zaghla HMA, El Sebai AA, Ahmed OA, et al. Growth differentiation factor 15: an emerging diagnostic biomarker of liver fibrosis in chronic hepatitis C patients. Egypt Liver J. 2021;11:6. https:\/\/doi.org\/10.1186\/s43066-021-00075-x.","journal-title":"Egypt Liver J"},{"key":"2336_CR84","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jgeb.2017.08.004","volume":"15","author":"MH Halim","year":"2017","unstructured":"Halim MH, Abdulla NA, Kamel A, et al. Significance of growth differentiation factor 15 in chronic HCV patients. J Genet Eng Biotechnol. 2017;15:403\u20137. https:\/\/doi.org\/10.1016\/j.jgeb.2017.08.004.","journal-title":"J Genet Eng Biotechnol"},{"issue":"12","key":"2336_CR85","doi-asserted-by":"publisher","first-page":"e0586","DOI":"10.1097\/HC9.0000000000000586","volume":"8","author":"M Lai","year":"2024","unstructured":"Lai M, Dillon ST, Gu X, et al. Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis. Hepatol Commun. 2024;8(12):e0586. https:\/\/doi.org\/10.1097\/HC9.0000000000000586.","journal-title":"Hepatol Commun"},{"key":"2336_CR86","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/hiv.70060","volume":"26","author":"P Debroy","year":"2025","unstructured":"Debroy P, Pike F, Gawrieh S, et al. Circulating fibroblast growth factor 21 and growth differentiation factor 15 are associated with severity of hepatic steatosis in people with HIV. HIV Med. 2025;26:1457\u201362. https:\/\/doi.org\/10.1111\/hiv.70060.","journal-title":"HIV Med"},{"key":"2336_CR87","doi-asserted-by":"publisher","first-page":"e59433","DOI":"10.7759\/cureus.59433","volume":"16","author":"R Ono","year":"2024","unstructured":"Ono R, Takayama S, Abe M, et al. Growth differentiation factor-15 is considered a predictive biomarker of long COVID in non-hospitalized patients. Cureus. 2024;16:e59433. https:\/\/doi.org\/10.7759\/cureus.59433.","journal-title":"Cureus"},{"key":"2336_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154496","author":"T Kljakovic-Gaspic","year":"2022","unstructured":"Kljakovic-Gaspic T, Tokic D, Martinovic D, et al. Prognostic value of catestatin in severe COVID-19: an ICU-based study. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11154496.","journal-title":"J Clin Med"},{"key":"2336_CR89","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s40001-023-01514-8","volume":"28","author":"SR Ishak","year":"2023","unstructured":"Ishak SR, Ganzoury MME, Fouda EM, et al. Serum growth differentiation factor-15 (GDF-15) is a biomarker of cardiac manifestations in children with COVID-19. Eur J Med Res. 2023;28:527. https:\/\/doi.org\/10.1186\/s40001-023-01514-8.","journal-title":"Eur J Med Res"},{"key":"2336_CR90","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.2147\/IDR.S468298","volume":"17","author":"D Ji","year":"2024","unstructured":"Ji D, Li J, Liu A, et al. Predictive value of combined detection of serum LGALS3BP and GDF-15 for the prognosis of ICU sepsis patients. Infect Drug Resist. 2024;17:4417\u201326. https:\/\/doi.org\/10.2147\/IDR.S468298.","journal-title":"Infect Drug Resist"},{"key":"2336_CR91","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13075-018-1777-7","volume":"20","author":"SY Kawashiri","year":"2018","unstructured":"Kawashiri SY, Origuchi T, Umeda M, et al. Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease. Arthritis Res Ther. 2018;20:277. https:\/\/doi.org\/10.1186\/s13075-018-1777-7.","journal-title":"Arthritis Res Ther"},{"key":"2336_CR92","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cca.2020.05.004","volume":"507","author":"G Li","year":"2020","unstructured":"Li G, Wang T, Li J, et al. Increased concentrations of growth differentiation factor-15 in children with Kawasaki disease. Clin Chim Acta. 2020;507:264\u201370. https:\/\/doi.org\/10.1016\/j.cca.2020.05.004.","journal-title":"Clin Chim Acta"},{"key":"2336_CR93","doi-asserted-by":"publisher","first-page":"e13564","DOI":"10.1111\/ijcp.13564","volume":"74","author":"K Esalatmanesh","year":"2020","unstructured":"Esalatmanesh K, Fayyazi H, Esalatmanesh R, et al. The association between serum levels of growth differentiation factor-15 and rheumatoid arthritis activity. Int J Clin Pract. 2020;74:e13564. https:\/\/doi.org\/10.1111\/ijcp.13564.","journal-title":"Int J Clin Pract"},{"key":"2336_CR94","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1302\/2046-3758.145.BJR-2024-0230.R2","volume":"14","author":"X Liu","year":"2025","unstructured":"Liu X, Essien AE, Lu W, et al. Growth differentiation factor 15 as a potential diagnostic biomarker for rheumatoid arthritis\u202f: a systematic review. Bone J Res. 2025;14:389\u201397. https:\/\/doi.org\/10.1302\/2046-3758.145.BJR-2024-0230.R2.","journal-title":"Bone J Res"},{"key":"2336_CR95","doi-asserted-by":"publisher","first-page":"20007","DOI":"10.1038\/s41598-025-03698-x","volume":"15","author":"J Fu","year":"2025","unstructured":"Fu J, Peng W, Wu Q, et al. Serum growth differentiation factor 15 associates with extra-glandular manifestations and disease activity of primary Sj\u00f6gren\u2019s syndrome. Sci Rep. 2025;15:20007. https:\/\/doi.org\/10.1038\/s41598-025-03698-x.","journal-title":"Sci Rep"},{"key":"2336_CR96","doi-asserted-by":"publisher","first-page":"926373","DOI":"10.3389\/fimmu.2022.926373","volume":"13","author":"WD Xu","year":"2022","unstructured":"Xu WD, Huang Q, Yang C, et al. GDF-15: a potential biomarker and therapeutic target in systemic lupus erythematosus. Front Immunol. 2022;13:926373. https:\/\/doi.org\/10.3389\/fimmu.2022.926373.","journal-title":"Front Immunol"},{"key":"2336_CR97","doi-asserted-by":"publisher","first-page":"e12195","DOI":"10.1002\/pul2.12195","volume":"13","author":"J Qian","year":"2023","unstructured":"Qian J, Ding Y, Yang X, et al. The diagnostic and prognostic value of growth differentiation factor-15 in systemic lupus erythematosus-associated pulmonary arterial hypertension. Pulm Circ. 2023;13:e12195. https:\/\/doi.org\/10.1002\/pul2.12195.","journal-title":"Pulm Circ"},{"key":"2336_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf468","author":"D Yildirim","year":"2025","unstructured":"Yildirim D, Erden A, Ibrahimkhanli N, et al. A new characterist\u0131c of systemic lupus erythematosus: subclinical vein involvement\u2014an in-depth biochemical and imaging study. Rheumatology (Oxford). 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf468.","journal-title":"Rheumatology (Oxford)"},{"key":"2336_CR99","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/art.38241","volume":"66","author":"S Lambrecht","year":"2014","unstructured":"Lambrecht S, Smith V, De Wilde K, et al. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Arthritis Rheumatol. 2014;66:418\u201327. https:\/\/doi.org\/10.1002\/art.38241.","journal-title":"Arthritis Rheumatol"},{"key":"2336_CR100","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/08820139.2017.1360340","volume":"46","author":"SM Gamal","year":"2017","unstructured":"Gamal SM, Elgengehy FT, Kamal A, et al. Growth differentiation factor-15 (GDF-15) level and relation to clinical manifestations in Egyptian systemic sclerosis patients: preliminary data. Immunol Invest. 2017;46:703\u201313. https:\/\/doi.org\/10.1080\/08820139.2017.1360340.","journal-title":"Immunol Invest"},{"key":"2336_CR101","doi-asserted-by":"publisher","first-page":"e13733","DOI":"10.1097\/MD.0000000000013733","volume":"97","author":"Y Song","year":"2018","unstructured":"Song Y, Cui Y, Zhang X, et al. Increased serum levels of MIC1\/GDF15 correlated with bone erosion in spondyloarthritis: a pilot study. Medicine (Baltimore). 2018;97:e13733. https:\/\/doi.org\/10.1097\/MD.0000000000013733.","journal-title":"Medicine (Baltimore)"},{"key":"2336_CR102","first-page":"363","volume":"32","author":"A Modi","year":"2021","unstructured":"Modi A, Purohit P, Gadwal A, et al. A combined analysis of serum growth differentiation factor-15 and cancer antigen 15-3 enhances the diagnostic efficiency in breast cancer. EJIFCC. 2021;32:363\u201376.","journal-title":"EJIFCC"},{"key":"2336_CR103","doi-asserted-by":"publisher","first-page":"1396133","DOI":"10.3389\/fphar.2024.1396133","volume":"15","author":"C Tian","year":"2024","unstructured":"Tian C, Zhang H, Liu J, et al. GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy. Front Pharmacol. 2024;15:1396133. https:\/\/doi.org\/10.3389\/fphar.2024.1396133.","journal-title":"Front Pharmacol"},{"key":"2336_CR104","doi-asserted-by":"publisher","first-page":"24892","DOI":"10.18632\/oncotarget.15279","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Yang Z, Tian H, et al. Circulating MIC-1\/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget. 2017;8:24892\u2013901. https:\/\/doi.org\/10.18632\/oncotarget.15279.","journal-title":"Oncotarget"},{"key":"2336_CR105","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1021\/pr9008817","volume":"9","author":"H Xue","year":"2010","unstructured":"Xue H, L\u00fc B, Zhang J, et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res. 2010;9:545\u201355. https:\/\/doi.org\/10.1021\/pr9008817.","journal-title":"J Proteome Res"},{"key":"2336_CR106","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/apt.14156","volume":"46","author":"M Danta","year":"2017","unstructured":"Danta M, Barber DA, Zhang HP, et al. Macrophage inhibitory cytokine-1\/growth differentiation factor-15 as a predictor of colonic neoplasia. Aliment Pharmacol Ther. 2017;46:347\u201354. https:\/\/doi.org\/10.1111\/apt.14156.","journal-title":"Aliment Pharmacol Ther"},{"key":"2336_CR107","doi-asserted-by":"publisher","first-page":"e0127518","DOI":"10.1371\/journal.pone.0127518","volume":"10","author":"X Liu","year":"2015","unstructured":"Liu X, Chi X, Gong Q, et al. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma. PLoS ONE. 2015;10:e0127518. https:\/\/doi.org\/10.1371\/journal.pone.0127518.","journal-title":"PLoS ONE"},{"key":"2336_CR108","doi-asserted-by":"publisher","first-page":"1619387","DOI":"10.3389\/fimmu.2025.1619387","volume":"16","author":"R Xing","year":"2025","unstructured":"Xing R, Gan J, Mei J, et al. Serum GDF15 level as predictive biomarker of clinical outcome in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Front Immunol. 2025;16:1619387. https:\/\/doi.org\/10.3389\/fimmu.2025.1619387.","journal-title":"Front Immunol"},{"key":"2336_CR109","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.clinthera.2021.02.001","volume":"43","author":"J Deng","year":"2021","unstructured":"Deng J, Zhang M, Zhang H, et al. Value of growth\/differentiation factor 15 in diagnosis and the evaluation of chemotherapeutic response in lung cancer. Clin Ther. 2021;43:747\u201359. https:\/\/doi.org\/10.1016\/j.clinthera.2021.02.001.","journal-title":"Clin Ther"},{"key":"2336_CR110","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00417-011-1786-6","volume":"250","author":"D Suesskind","year":"2012","unstructured":"Suesskind D, Schatz A, Schnichels S, et al. GDF-15: a novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol. 2012;250:887\u201395. https:\/\/doi.org\/10.1007\/s00417-011-1786-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2336_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102464","author":"Z Lin","year":"2021","unstructured":"Lin Z, S\u00fcsskind D. Evaluation of a three-marker panel for the detection of uveal melanoma metastases: a single-center retrospective analysis. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13102464.","journal-title":"Cancers (Basel)"},{"key":"2336_CR112","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.jid.2016.07.016","volume":"136","author":"B Weide","year":"2016","unstructured":"Weide B, Sch\u00e4fer T, Martens A, et al. High GDF-15 serum levels independently correlate with poorer overall survival of patients with tumor-free stage III and unresectable stage IV melanoma. J Invest Dermatol. 2016;136:2444\u201352. https:\/\/doi.org\/10.1016\/j.jid.2016.07.016.","journal-title":"J Invest Dermatol"},{"key":"2336_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194842","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Mitsunaga S, Ikeda M, et al. Clinical and tumor characteristics of patients with high serum levels of growth differentiation factor 15 in advanced pancreatic cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13194842.","journal-title":"Cancers (Basel)"},{"key":"2336_CR114","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pan.2014.10.008","volume":"15","author":"AA Mohamed","year":"2015","unstructured":"Mohamed AA, Soliman H, Ismail M, et al. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer. Pancreatology. 2015;15:34\u20139. https:\/\/doi.org\/10.1016\/j.pan.2014.10.008.","journal-title":"Pancreatology"},{"key":"2336_CR115","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3233\/CBM-170203","volume":"21","author":"P Hogendorf","year":"2018","unstructured":"Hogendorf P, Durczy\u0144ski A, Skulimowski A, et al. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. Cancer Biomark. 2018;21:505\u201311. https:\/\/doi.org\/10.3233\/CBM-170203.","journal-title":"Cancer Biomark"},{"key":"2336_CR116","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/1471-2407-14-578","volume":"14","author":"X Wang","year":"2014","unstructured":"Wang X, Li Y, Tian H, et al. Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2014;14:578. https:\/\/doi.org\/10.1186\/1471-2407-14-578.","journal-title":"BMC Cancer"},{"key":"2336_CR117","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3748\/wjg.v26.i14.1660","volume":"26","author":"RS O'Neill","year":"2020","unstructured":"O\u2019Neill RS, Emmanuel S, Williams D, et al. Macrophage inhibitory cytokine-1\/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort. World J Gastroenterol. 2020;26:1660\u201373. https:\/\/doi.org\/10.3748\/wjg.v26.i14.1660.","journal-title":"World J Gastroenterol"},{"key":"2336_CR118","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1158\/1078-0432.ccr-03-0165","volume":"10","author":"J Koopmann","year":"2004","unstructured":"Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386\u201392. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0165.","journal-title":"Clin Cancer Res"},{"key":"2336_CR119","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1158\/1078-0432.CCR-05-0564","volume":"12","author":"J Koopmann","year":"2006","unstructured":"Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0564.","journal-title":"Clin Cancer Res"},{"key":"2336_CR120","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1038\/s41598-017-17207-2","volume":"7","author":"N Bansal","year":"2017","unstructured":"Bansal N, Kumar D, Gupta A, et al. Relevance of MIC-1 in the era of PSA as a serum based predictor of prostate cancer: a critical evaluation. Sci Rep. 2017;7:16824. https:\/\/doi.org\/10.1038\/s41598-017-17207-2.","journal-title":"Sci Rep"},{"key":"2336_CR121","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1055-9965.EPI-06-0841","volume":"16","author":"KS Selander","year":"2007","unstructured":"Selander KS, Brown DA, Sequeiros GB, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomark Prev. 2007;16:532\u20137. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0841.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2336_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010099","author":"A Molfino","year":"2020","unstructured":"Molfino A, Amabile MI, Imbimbo G, et al. Association between growth differentiation factor-15 (GDF-15) serum levels, anorexia and low muscle mass among cancer patients. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers13010099.","journal-title":"Cancers (Basel)"},{"key":"2336_CR123","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/hepr.14148","volume":"55","author":"MP Werge","year":"2025","unstructured":"Werge MP, Grandt J, Thing M, et al. Circulating and hepatic levels of growth differentiation factor 15 in patients with metabolic dysfunction-associated steatotic liver disease. Hepatol Res. 2025;55:492\u2013504. https:\/\/doi.org\/10.1111\/hepr.14148.","journal-title":"Hepatol Res"},{"key":"2336_CR124","doi-asserted-by":"publisher","first-page":"8759","DOI":"10.1038\/s41598-022-12762-9","volume":"12","author":"T Arinaga-Hino","year":"2022","unstructured":"Arinaga-Hino T, Ide T, Akiba J, et al. Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis. Sci Rep. 2022;12:8759. https:\/\/doi.org\/10.1038\/s41598-022-12762-9.","journal-title":"Sci Rep"},{"key":"2336_CR125","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","volume":"14","author":"CN Jenne","year":"2013","unstructured":"Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14:996\u20131006. https:\/\/doi.org\/10.1038\/ni.2691.","journal-title":"Nat Immunol"},{"issue":"1","key":"2336_CR126","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.1038\/s41467-024-51078-2","volume":"15","author":"L L'homme","year":"2024","unstructured":"L\u2019homme L, Sermikli BP, Haas JT, et al. Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH. Nat Commun. 2024;15(1):7173. https:\/\/doi.org\/10.1038\/s41467-024-51078-2.","journal-title":"Nat Commun"},{"key":"2336_CR127","doi-asserted-by":"publisher","first-page":"101478","DOI":"10.1016\/j.jhepr.2025.101478","volume":"7","author":"T Rubio-Tom\u00e1s","year":"2025","unstructured":"Rubio-Tom\u00e1s T, Mart\u00ed-Aguado D, Blaya D, et al. GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis. JHEP Rep. 2025;7:101478. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101478.","journal-title":"JHEP Rep"},{"key":"2336_CR128","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.tem.2021.08.008","volume":"32","author":"S Keipert","year":"2021","unstructured":"Keipert S, Ost M. Stress-induced FGF21 and GDF15 in obesity and obesity resistance. Trends Endocrinol Metab. 2021;32:904\u201315. https:\/\/doi.org\/10.1016\/j.tem.2021.08.008.","journal-title":"Trends Endocrinol Metab"},{"key":"2336_CR129","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/liv.13587","volume":"38","author":"BK Koo","year":"2018","unstructured":"Koo BK, Um SH, Seo DS, et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2018;38:695\u2013705. https:\/\/doi.org\/10.1111\/liv.13587.","journal-title":"Liver Int"},{"key":"2336_CR130","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2468-1253(23)00111-5","volume":"8","author":"S Affo","year":"2023","unstructured":"Affo S, Filliol A, Gores GJ, et al. Fibroblasts in liver cancer: functions and therapeutic translation. Lancet Gastroenterol Hepatol. 2023;8:748\u201359. https:\/\/doi.org\/10.1016\/S2468-1253(23)00111-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2336_CR131","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1038\/s41598-018-25098-0","volume":"8","author":"KH Kim","year":"2018","unstructured":"Kim KH, Kim SH, Han DH, et al. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Sci Rep. 2018;8:6789. https:\/\/doi.org\/10.1038\/s41598-018-25098-0.","journal-title":"Sci Rep"},{"key":"2336_CR132","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/01.RES.0000202804.84885.d0","volume":"98","author":"J Xu","year":"2006","unstructured":"Xu J, Kimball TR, Lorenz JN, et al. GDF15\/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98:342\u201350. https:\/\/doi.org\/10.1161\/01.RES.0000202804.84885.d0.","journal-title":"Circ Res"},{"key":"2336_CR133","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/hepr.13932","volume":"53","author":"TH Su","year":"2023","unstructured":"Su TH, Chang SH, Chen CL, et al. Serial increase and high alpha-fetoprotein levels predict the development of hepatocellular carcinoma in 6 months. Hepatol Res. 2023;53:1021\u201330. https:\/\/doi.org\/10.1111\/hepr.13932.","journal-title":"Hepatol Res"},{"key":"2336_CR134","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jcsm.13513","volume":"15","author":"RS Kamper","year":"2024","unstructured":"Kamper RS, Nygaard H, Praeger-Jahnsen L, et al. GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients. J Cachexia Sarcopenia Muscle. 2024;15:1549\u201357. https:\/\/doi.org\/10.1002\/jcsm.13513.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2336_CR135","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/gerona\/glab201","volume":"77","author":"M Kim","year":"2022","unstructured":"Kim M, Walston JD, Won CW. Associations between elevated growth differentiation factor-15 and sarcopenia among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2022;77:770\u201380. https:\/\/doi.org\/10.1093\/gerona\/glab201.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2336_CR136","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","volume":"50","author":"T Kempf","year":"2007","unstructured":"Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2007.04.091.","journal-title":"J Am Coll Cardiol"},{"key":"2336_CR137","doi-asserted-by":"publisher","first-page":"e8023","DOI":"10.1161\/JAHA.122.026003","volume":"12","author":"MS Binder","year":"2023","unstructured":"Binder MS, Yanek LR, Yang W, et al. Growth differentiation factor-15 predicts mortality and heart failure exacerbation but not ventricular arrhythmias in patients with cardiomyopathy. J Am Heart Assoc. 2023;12:e8023. https:\/\/doi.org\/10.1161\/JAHA.122.026003.","journal-title":"J Am Heart Assoc"},{"key":"2336_CR138","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s42255-021-00368-w","volume":"3","author":"J Kim","year":"2021","unstructured":"Kim J, Kim SH, Kang H, et al. TFEB-GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response. Nat Metab. 2021;3:410\u201327. https:\/\/doi.org\/10.1038\/s42255-021-00368-w.","journal-title":"Nat Metab"},{"key":"2336_CR139","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molmet.2019.01.003","volume":"21","author":"H Frikke-Schmidt","year":"2019","unstructured":"Frikke-Schmidt H, Hultman K, Galaske JW, et al. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice. Mol Metab. 2019;21:13\u201321. https:\/\/doi.org\/10.1016\/j.molmet.2019.01.003.","journal-title":"Mol Metab"},{"key":"2336_CR140","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson PJ, Wang F, Du Y, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017;23:1215\u20139. https:\/\/doi.org\/10.1038\/nm.4393.","journal-title":"Nat Med"},{"key":"2336_CR141","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1210\/clinem\/dgae550","volume":"110","author":"WB Smith","year":"2025","unstructured":"Smith WB, Nguyen D, Clough T, et al. A growth differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons. J Clin Endocrinol Metab. 2025;110:771\u201386. https:\/\/doi.org\/10.1210\/clinem\/dgae550.","journal-title":"J Clin Endocrinol Metab"},{"key":"2336_CR142","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","volume":"14","author":"M Haake","year":"2023","unstructured":"Haake M, Haack B, Sch\u00e4fer T, et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat Commun. 2023;14:4253. https:\/\/doi.org\/10.1038\/s41467-023-39817-3.","journal-title":"Nat Commun"},{"key":"2336_CR143","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002787","author":"Z Wang","year":"2021","unstructured":"Wang Z, He L, Li W, et al. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002787.","journal-title":"J Immunother Cancer"},{"key":"2336_CR144","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/jcsm.13435","volume":"15","author":"JD Groarke","year":"2024","unstructured":"Groarke JD, Crawford J, Collins SM, et al. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J Cachexia Sarcopenia Muscle. 2024;15:1054\u201361. https:\/\/doi.org\/10.1002\/jcsm.13435.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2336_CR145","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00432-022-04500-5","volume":"149","author":"G Hong","year":"2023","unstructured":"Hong G, Sun P, Chung C, et al. Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1\/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2023;149:159\u201371. https:\/\/doi.org\/10.1007\/s00432-022-04500-5.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2336_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244146","author":"O Akdogan","year":"2024","unstructured":"Akdogan O, Turkmen S, Uyar GC, et al. Impact of serum GDF-15 and IL-6 on immunotherapy response in cancer: a prospective study. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16244146.","journal-title":"Cancers (Basel)"},{"key":"2336_CR147","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011220","author":"L Depotte","year":"2025","unstructured":"Depotte L, Nay P, Borg C, et al. Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-011220.","journal-title":"J Immunother Cancer"},{"key":"2336_CR148","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","volume":"637","author":"I Melero","year":"2025","unstructured":"Melero I, de Miguel Luken M, de Velasco G, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025;637:1218\u201327. https:\/\/doi.org\/10.1038\/s41586-024-08305-z.","journal-title":"Nature"},{"key":"2336_CR149","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12288-020-01315-7","volume":"37","author":"HM Hegab","year":"2021","unstructured":"Hegab HM, El-Ghammaz AMS, El-Razzaz MK, et al. Prognostic impact of serum growth differentiation factor 15 level in acute myeloid leukemia patients. Indian J Hematol Blood Transfus. 2021;37:37\u201344. https:\/\/doi.org\/10.1007\/s12288-020-01315-7.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2336_CR150","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jop.12091","volume":"43","author":"CZ Yang","year":"2014","unstructured":"Yang CZ, Ma J, Luo QQ, et al. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma. J Oral Pathol Med. 2014;43:28\u201334. https:\/\/doi.org\/10.1111\/jop.12091.","journal-title":"J Oral Pathol Med"},{"key":"2336_CR151","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.oraloncology.2012.01.020","volume":"48","author":"E Schiegnitz","year":"2012","unstructured":"Schiegnitz E, K\u00e4mmerer PW, Koch FP, et al. GDF 15 as an anti-apoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma. Oral Oncol. 2012;48:608\u201314. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.01.020.","journal-title":"Oral Oncol"},{"key":"2336_CR152","doi-asserted-by":"publisher","first-page":"1404063","DOI":"10.3389\/fnut.2024.1404063","volume":"11","author":"G Shi","year":"2024","unstructured":"Shi G, Yue L, Tang Z, et al. Serum growth differentiation factor 15 as a biomarker for malnutrition in patients with acute exacerbation of chronic obstructive pulmonary disease. Front Nutr. 2024;11:1404063. https:\/\/doi.org\/10.3389\/fnut.2024.1404063.","journal-title":"Front Nutr"},{"key":"2336_CR153","doi-asserted-by":"publisher","first-page":"897097","DOI":"10.3389\/fnut.2022.897097","volume":"9","author":"M Deng","year":"2022","unstructured":"Deng M, Bian Y, Zhang Q, et al. Growth differentiation factor-15 as a biomarker for sarcopenia in patients with chronic obstructive pulmonary disease. Front Nutr. 2022;9:897097. https:\/\/doi.org\/10.3389\/fnut.2022.897097.","journal-title":"Front Nutr"},{"key":"2336_CR154","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/10245332.2017.1311462","volume":"22","author":"Y Shao","year":"2017","unstructured":"Shao Y, Wang H, Liu C, et al. Transforming growth factor 15 increased in severe aplastic anemia patients. Hematology. 2017;22:548\u201353. https:\/\/doi.org\/10.1080\/10245332.2017.1311462.","journal-title":"Hematology"},{"key":"2336_CR155","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/jha2.415","volume":"3","author":"A Efat","year":"2022","unstructured":"Efat A, Wahb R, Shoeib SAA, et al. GDF-15 is associated with atherosclerosis in adults with transfusion-dependent beta-thalassemia. EJHaem. 2022;3:353\u201361. https:\/\/doi.org\/10.1002\/jha2.415.","journal-title":"EJHaem"},{"key":"2336_CR156","first-page":"5617","volume":"13","author":"X Liu","year":"2021","unstructured":"Liu X. Changes and significance of serum CXCL-16, GDF-15, PLA-2 levels in patients with cerebral infarction. Am J Transl Res. 2021;13:5617\u201322.","journal-title":"Am J Transl Res"},{"key":"2336_CR157","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000477349","volume":"17","author":"X Yao","year":"2017","unstructured":"Yao X, Wang D, Zhang L, et al. Serum growth differentiation factor 15 in Parkinson disease. Neurodegener Dis. 2017;17:251\u201360. https:\/\/doi.org\/10.1159\/000477349.","journal-title":"Neurodegener Dis"},{"key":"2336_CR158","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3345\/cep.2025.00416","volume":"68","author":"AH Bakri","year":"2025","unstructured":"Bakri AH, Hassan MH, Abd-Elbaseer KA, et al. Association of macrophage migration-inhibitory factor gene and growth differentiation factor 15 gene polymorphisms and their circulating levels with respiratory distress syndrome among preterm neonates. Clin Exp Pediatr. 2025;68:680\u20139. https:\/\/doi.org\/10.3345\/cep.2025.00416.","journal-title":"Clin Exp Pediatr"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02336-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:41:33Z","timestamp":1771659693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02336-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":158,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02336-7","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to disclose regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}